Quipt Home Medical Corp. (NASDAQ:QIPT) Q3 2024 Results Conference Call August 15, 2024 10:00 AM ET

Company Participants

Greg Crawford - Chairman, CEO
Hardik Mehta - CFO

Conference Call Participants

Richard Close - Canaccord Genuity
Justin Keywood - Stifel
Stefan Quenneville - Venton Financial

Operator

Thank you for standing by. This is the conference operator. Welcome to the Fiscal Third Quarter 2024 Results Conference Call for Quipt Home Medical Corp. As a reminder all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity for analyst to ask questions. [Operator Instructions]

We remind you that the remarks today will include forward-looking statements that are subject to important risks and uncertainties. For more information on these risks and uncertainties, please see the reader advisory at the bottom of the Company's results news release. The Company's actual performance could differ materially from these statements.

At this point, I'd like to turn the call over to Chairman and Chief Executive Officer, Greg Crawford.

Greg Crawford

Thank you, operator, and thank you all for joining us today on the call. My name is Greg Crawford, and I'm the Chairman and Chief Executive Officer of Quipt Home Medical. Joining me today is Hardik Mehta, our Chief Financial Officer. Quipt Home Medical is a diversified health care services company, providing a full spectrum of home medical equipment and services to patients in the home setting across the United States.

At Quip, our unwavering commitment is to provide clinical excellence through our patient-centric ecosystem, leveraging technology-enabled equipment solutions in conjunction with our specialized clinical respiratory programs to effectively treat patients at home in a way that best suits their needs.

Our core go-to-market strategy drives market penetration through providing an end-to-end respiratory care solution with complementary durable medical equipment products to our key sales touch points serving as a one-stop shop in the marketplace. At this time, respiratory care accounts for approximately 80% of our product mix showcasing our ongoing commitment to serving the needs of patients with pulmonary and cardiovascular diseases.

With our ongoing dedication to patient care and the scale we are achieving, we are poised to capitalize on the expanding need for respiratory care delivered in the home setting. This need for respiratory care is driven by an aging population significant COPD target patient group of over 16 million Americans and a significantly underpenetrated sleep apnea market with OSA impacting 80 million adults across the United States.